Form 4: Nurix Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Houte Hans Van, Chief Financial Officer of Nurix Therapeutics, Inc., sold 4,761 shares of common stock on August 4, 2026.
Summary
- Open-market sale: disposed of 1,794 Common Stock at $23.89 ($42,861) on August 4, 2026; holds 43,133 after (Direct).
- Open-market sale: disposed of 2,967 Common Stock at $24.65 ($73,129) on August 4, 2026; holds 40,166 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $115,989 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Houte Hans Van — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-04 | Open-market sale | Common Stock | 1,794 | $24 | $42.9K | 43,133 |
| 2026-08-04 | Open-market sale | Common Stock | 2,967 | $25 | $73.1K | 40,166 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-04 | Open-market sale (1,794 shares) |
| 2026-08-04 | Open-market sale (2,967 shares) |
Keywords
insider transaction, Form 4, NRIX, Nurix Therapeutics, Inc., bearish, Houte Hans Van
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.